The blood-brain barrier: Structure, function and therapeutic approaches to cross it

Abstract The blood-brain barrier (BBB) is constituted by a specialized vascular endothelium that interacts directly with astrocytes, neurons and pericytes. It protects the brain from the molecules of the systemic circulation but it has to be overcome for the proper treatment of brain cancer, psychiatric disorders or neurodegenerative diseases, which are dramatically increasing as the population ages. In the present work we have revised the current knowledge on the cellular structure of the BBB and the different procedures utilized currently and those proposed to cross it. Chemical modifications of the drugs, such as increasing their lipophilicity, turn them more prone to be internalized in the brain. Other mechanisms are the use of molecular tools to bind the drugs such as small immunoglobulins, liposomes or nanoparticles that will act as Trojan Horses favoring the drug delivery in brain. This fusion of the classical pharmacology with nanotechnology has opened a wide field to many different approaches with promising results to hypothesize that BBB will not be a major problem for the new generation of neuroactive drugs. The present review provides an overview of all state-of-the-art of the BBB structure and function, as well as of the classic strategies and these appeared in recent years to deliver drugs into the brain for the treatment of Central Nervous System (CNS) diseases.

[1]  Henry Brem,et al.  Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[2]  A. Ávila-Flores,et al.  MAGUK proteins: structure and role in the tight junction. , 2000, Seminars in cell & developmental biology.

[3]  G. Pitarresi,et al.  Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System , 2011, CNS neuroscience & therapeutics.

[4]  Rachel C Brown,et al.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells , 2007, Brain Research.

[5]  A. Schatzlein,et al.  Strategies to deliver peptide drugs to the brain. , 2014, Molecular pharmaceutics.

[6]  R. Keep,et al.  Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier , 2008, Current neuropharmacology.

[7]  W. Pardridge,et al.  Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.

[8]  Jean-Christophe Olivier,et al.  Drug transport to brain with targeted nanoparticles , 2011, NeuroRX.

[9]  K. Furuuchi,et al.  Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. , 1999, Biochemical and biophysical research communications.

[10]  B. Engelhardt,et al.  The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.

[11]  L. Rubin,et al.  The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.

[12]  M. Takeichi,et al.  Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. , 1989, Cell regulation.

[13]  Char-Huei Lai,et al.  The critical component to establish in vitro BBB model: Pericyte , 2005, Brain Research Reviews.

[14]  D. Kwiatkowski,et al.  Tumour necrosis factor, fever and fatality in falciparum malaria. , 1990, Immunology letters.

[15]  J M Scherrmann,et al.  Drug delivery to brain via the blood-brain barrier. , 2002, Vascular pharmacology.

[16]  K. Elisevich,et al.  Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. , 1994, Journal of neurosurgery.

[17]  N J Abbott,et al.  Electrical resistance across the blood‐brain barrier in anaesthetized rats: a developmental study. , 1990, The Journal of physiology.

[18]  I. Wilhelm,et al.  In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.

[19]  E. Pasquale,et al.  Tyrosine phosphorylated proteins in different tissues during chick embryo development , 1988, The Journal of cell biology.

[20]  Natalia Vykhodtseva,et al.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. , 2008, Ultrasonics.

[21]  P. Dickson Delivering drugs to the central nervous system: an overview , 2012, Drug Delivery and Translational Research.

[22]  Transplanting bone-marrow stem cells in the central nervous system. , 2000, Haematologica.

[23]  Lucienne Juillerat-Jeanneret,et al.  The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.

[24]  C P Ponting,et al.  PDZ Domains: Targeting signalling molecules to sub‐membranous sites , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  M. Frank The reticuloendothelial system and bloodstream clearance. , 1993, The Journal of laboratory and clinical medicine.

[26]  G. Lapin,et al.  Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. , 1999, Microvascular research.

[27]  S. Moochhala,et al.  Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. , 2008, Biopolymers.

[28]  Yan Zhang,et al.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[29]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[30]  W. Pardridge New approaches to drug delivery through the blood-brain barrier. , 1994, Trends in biotechnology.

[31]  P. Cancilla,et al.  Neutral Amino Acid Transport Properties of Cerebral Endothelial Cells in Vitro , 1983, Journal of neuropathology and experimental neurology.

[32]  E. Neuwelt Mechanisms of Disease: The Blood-Brain Barrier , 2004, Neurosurgery.

[33]  Zhirong Zhang,et al.  Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. , 2011, International journal of pharmaceutics.

[34]  J. Bading,et al.  Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy , 1998, Journal of neurochemistry.

[35]  I. Fichtner,et al.  Improving the transport of chemotherapeutic drugs across the blood–brain barrier , 2011, Expert review of clinical pharmacology.

[36]  A. Trapani,et al.  In vitro evaluation on a model of blood brain barrier of idebenone-loaded solid lipid nanoparticles. , 2012, Journal of nanoscience and nanotechnology.

[37]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[38]  H. Okada,et al.  Intranasal Delivery of Camptothecin-Loaded Tat-Modified Nanomicells for Treatment of Intracranial Brain Tumors , 2012, Pharmaceuticals.

[39]  Anna Forsby,et al.  Blood-brain barrier in vitro models and their application in toxicology - The report and recommendations of ECVAM workshop 49 , 2004 .

[40]  C. Ropert,et al.  Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. , 1992, Biomaterials.

[41]  W. Scheld,et al.  Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. , 1989, Reviews of infectious diseases.

[42]  M. Hatzfeld The p120 family of cell adhesion molecules. , 2005, European journal of cell biology.

[43]  E. Lo,et al.  Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation , 2002, Progress in Neurobiology.

[44]  Wolfgang Löscher,et al.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.

[45]  B. Engelhardt Development of the blood-brain barrier , 2003, Cell and Tissue Research.

[46]  B. Barres,et al.  Induction of Astrocyte Differentiation by Endothelial Cells , 2001, The Journal of Neuroscience.

[47]  Coecke Sandra,et al.  Blood-Brain Barrier invitro Models and their Application in Toxicology. , 2004 .

[48]  M. Brightman,et al.  Nonpermeable and permeable vessels of the brain. , 1992, NIDA research monograph.

[49]  M. Ricci,et al.  Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.

[50]  T. Mayumi,et al.  Preparation of glial extracellular matrix: a novel method to analyze glial-endothelial cell interaction. , 1997, Brain research. Brain research protocols.

[51]  Hyun Seok Song,et al.  SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier , 2003, Nature Medicine.

[52]  Hiroshi Yamamoto,et al.  Induction of various blood‐brain barrier properties in non‐neural endothelial cells by close apposition to co‐cultured astrocytes , 1997, Glia.

[53]  R. Janzer,et al.  Astrocytes induce blood–brain barrier properties in endothelial cells , 1987, Nature.

[54]  R B Wysolmerski,et al.  Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization, and myosin phosphorylation , 1995, The Journal of cell biology.

[55]  I. Tamai,et al.  Transporter-mediated permeation of drugs across the blood-brain barrier. , 2000, Journal of pharmaceutical sciences.

[56]  A. Verkman,et al.  Aquaporin water channels and endothelial cell function * , 2002, Journal of anatomy.

[57]  W. Pardridge,et al.  Combination stroke therapy in the mouse with blood–brain barrier penetrating IgG–GDNF and IgG–TNF decoy receptor fusion proteins , 2013, Brain Research.

[58]  J. Stow,et al.  Protein trafficking and polarity in kidney epithelium: from cell biology to physiology. , 1996, Physiological reviews.

[59]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[60]  Yuanjun Zhu,et al.  Neuroprotective Effect of TAT-14-3-3ε Fusion Protein against Cerebral Ischemia/Reperfusion Injury in Rats , 2014, PloS one.

[61]  D. A. Quarles,et al.  Progress and problems , 1953, Electrical Engineering.

[62]  D. Shore,et al.  Cingulin Contains Globular and Coiled-Coil Domains and Interacts with Zo-1, Zo-2, Zo-3, and Myosin , 1999, The Journal of cell biology.

[63]  R. Thorne,et al.  Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.

[64]  N. Kawai,et al.  Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. , 1996, Journal of neurosurgery.

[65]  W. Frey,et al.  Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.

[66]  V. Labhasetwar,et al.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.

[67]  H. Steinbusch,et al.  Delivery of peptide and protein drugs over the blood–brain barrier , 2009, Progress in Neurobiology.

[68]  G. Bazzoni Endothelial tight junctions: permeable barriers of the vessel wall , 2005, Thrombosis and Haemostasis.

[69]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[70]  L. Rubin,et al.  A cell culture model of the blood-brain barrier , 1991, The Journal of cell biology.

[71]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[72]  Qin He,et al.  Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[73]  G. Miller Breaking Down Barriers , 2002, Science.

[74]  M. Ricci,et al.  Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? , 2006, Current medicinal chemistry.

[75]  N. Abbott,et al.  Astrocyte–endothelial interactions and blood–brain barrier permeability * , 2002 .

[76]  W. Geldenhuys,et al.  Novel models for assessing blood–brain barrier drug permeation , 2012, Expert opinion on drug metabolism & toxicology.

[77]  B. Gumbiner,et al.  Structure, biochemistry, and assembly of epithelial tight junctions. , 1987, The American journal of physiology.

[78]  L. Rubin,et al.  Cell adhesion, cell junctions and the blood—brain barrier , 1996, Current Opinion in Neurobiology.

[79]  M. Wiley,et al.  Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras. , 1981, Developmental biology.

[80]  S Esser,et al.  Cell confluence regulates tyrosine phosphorylation of adherens junction components in endothelial cells. , 1997, Journal of cell science.

[81]  Elisabetta Dejana,et al.  Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. , 2004, Physiological reviews.

[82]  S. Hemmerich,et al.  Vascular Endothelial Junction-associated Molecule, a Novel Member of the Immunoglobulin Superfamily, Is Localized to Intercellular Boundaries of Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[83]  W H Oldendorf,et al.  Kinetic analysis of blood-brain barrier transport of amino acids. , 1975, Biochimica et biophysica acta.

[84]  R. Langer,et al.  A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. , 1997, Journal of pharmaceutical sciences.

[85]  H. Galla,et al.  Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. , 2011, Biochemical and biophysical research communications.

[86]  R. Egleton,et al.  Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.

[87]  W. Pardridge,et al.  Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. , 1990, The Journal of pharmacology and experimental therapeutics.

[88]  R. Bendayan,et al.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.

[89]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[90]  M. Salcman,et al.  Transcytotic pathway for blood-borne protein through the blood-brain barrier. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Trapani,et al.  Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain. , 2009, Current topics in medicinal chemistry.

[92]  J. Firth,et al.  Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. , 1993, Journal of cell science.

[93]  A. Petrillo,et al.  Blood‐Brain Barrier Disruption for the Treatment of Malignant Brain Tumors: The National Program , 1998, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[94]  P. Vassalli,et al.  Tumor‐Necrosis Factor and other Cytokines in Cerebral Malaria: Experimental and Clinical Data , 1989, Immunological reviews.

[95]  P Delorme,et al.  An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro , 1990, Journal of neurochemistry.

[96]  W. Pardridge,et al.  Brain Delivery of Biotin Bound to a Conjugate of Neutral Avidin and Cationized Human Albumin , 1994, Pharmaceutical Research.

[97]  D. Lasič Novel applications of liposomes. , 1998, Trends in biotechnology.

[98]  T. Bui,et al.  Multiple protein interactions involving proposed extracellular loop domains of the tight junction protein occludin. , 2005, Molecular biology of the cell.

[99]  N. Yamamoto,et al.  Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors , 1999, Neuroscience Research.

[100]  Holger Gerhardt,et al.  Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis , 2001, The Journal of cell biology.

[101]  Y. Olsson,et al.  Observations on exsudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions , 2004, Acta Neuropathologica.

[102]  M. Fukui,et al.  Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. , 1996, Neurosurgery.

[103]  C. Coopersmith,et al.  Epithelial cells , 1991 .

[104]  K. Nakanishi,et al.  Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: A possible use of aortic endothelial cell for In vitro BBB model , 1996, Neurochemistry International.

[105]  Manini Patel,et al.  Solid Lipid Nanoparticles , 2014 .

[106]  L. Rubin,et al.  Occludin as a possible determinant of tight junction permeability in endothelial cells. , 1997, Journal of cell science.

[107]  Hanseup Kim,et al.  Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). , 2012, Lab on a chip.

[108]  V. Torchilin,et al.  Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[109]  S. Gloor,et al.  Co-culture blood-brain barrier models and their use for pharmatoxicological screening. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.

[110]  R. Udomsangpetch,et al.  In vitro study of malaria parasite induced disruption of blood-brain barrier. , 2005, Biochemical and biophysical research communications.

[111]  D. V. Kohli,et al.  Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil , 2005, Journal of drug targeting.

[112]  U. Christians,et al.  Ultrasound-Induced Mild Hyperthermia as a Novel Approach to Increase Drug Uptake in Brain Microvessel Endothelial Cells , 2002, Pharmaceutical Research.

[113]  Li Hai,et al.  Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes. , 2014, European journal of medicinal chemistry.

[114]  I. Blasig,et al.  In Search of the Astrocytic Factor(s) Modulating Blood–Brain Barrier Functions in Brain Capillary Endothelial Cells In Vitro , 2005, Cellular and Molecular Neurobiology.

[115]  S. K. Malhotra,et al.  Reactive astrocytes: cellular and molecular cues to biological function , 1997, Trends in Neurosciences.

[116]  M. Saitoh,et al.  Localization of 7H6 tight junction-associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. , 1996, Experimental cell research.

[117]  W. Pardridge,et al.  Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Te-Wei Lee,et al.  In Vitro and in Vivo Evaluation of Lactoferrin-Conjugated Liposomes as a Novel Carrier to Improve the Brain Delivery , 2013, International journal of molecular sciences.

[119]  G. Fricker,et al.  Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.

[120]  L. Illum Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[121]  J. Holly,et al.  The Role of Insulin-Like Growth Factor Binding Proteins , 2006, Neuroendocrinology.

[122]  G. Goldstein,et al.  Hexose transport in microvascular endothelial cells cultured from bovine retina. , 1983, Experimental eye research.

[123]  H. Newton,et al.  Advances in strategies to improve drug delivery to brain tumors , 2006, Expert review of neurotherapeutics.

[124]  L. Rubin,et al.  Dephosphorylation of the Cadherin-associated p100/p120 Proteins in Response to Activation of Protein Kinase C in Epithelial Cells* , 1997, The Journal of Biological Chemistry.

[125]  K. Jain,et al.  Use of nanoparticles for drug delivery in glioblastoma multiforme , 2007, Expert review of neurotherapeutics.

[126]  I. Herman,et al.  The pericyte: cellular regulator of microvascular blood flow. , 2009, Microvascular research.

[127]  Robert Langer,et al.  Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. , 2012, Biomaterials.

[128]  R. Egleton,et al.  Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. , 2004, American journal of physiology. Cell physiology.

[129]  R Langer,et al.  Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. , 1986, Journal of biomedical materials research.

[130]  R. Bartus,et al.  Intravenous Cereport (RMP-7) Enhances Delivery of Hydrophilic Chemotherapeutics and Increases Survival in Rats with Metastatic Tumors in the Brain , 2000, Pharmaceutical Research.

[131]  S. B. Tiwari,et al.  A review of nanocarrier-based CNS delivery systems. , 2006, Current drug delivery.

[132]  S I Simon,et al.  Analysis of tight junctions during neutrophil transendothelial migration. , 2000, Journal of cell science.

[133]  M. Khrestchatisky,et al.  Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery , 2013, Medicinal research reviews.

[134]  M. Schroeter,et al.  Astrocytes enhance radical defence in capillary endothelial cells constituting the blood‐brain barrier , 1999, FEBS letters.

[135]  N. Hogg,et al.  Identification and characterisation of human Junctional Adhesion Molecule (JAM). , 1999, Molecular immunology.

[136]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[137]  V. Perry,et al.  The blood-brain barrier and the inflammatory response. , 1997, Molecular medicine today.

[138]  P. Lantos,et al.  Hyperosmolar Opening of the Blood-Brain Barrier in the Energy-Depleted Rat Brain. Part 1. Permeability Studies , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[139]  J. Kreuter Drug targeting with nanoparticles , 1994, European Journal of Drug Metabolism and Pharmacokinetics.

[140]  M. Lakomek,et al.  Alkylglycerol opening of the blood–brain barrier to small and large fluorescence markers in normal and C6 glioma‐bearing rats and isolated rat brain capillaries , 2003, British journal of pharmacology.

[141]  Y. Nagai,et al.  PAR‐6 regulates aPKC activity in a novel way and mediates cell‐cell contact‐induced formation of the epithelial junctional complex , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[142]  M. Balda,et al.  Multiple domains of occludin are involved in the regulation of paracellular permeability , 2000, Journal of cellular biochemistry.

[143]  Mikko Gynther,et al.  Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.

[144]  R. Barth,et al.  Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates , 2006, Molecular Cancer Therapeutics.

[145]  K. Maclean,et al.  Neural Stem Cells Reduce Hippocampal Tau and Reelin Accumulation in Aged Ts65Dn down Syndrome Mice , 2011, Cell transplantation.

[146]  J. Bulte,et al.  Neural progenitor cell survival in mouse brain can be improved by co-transplantation of helper cells expressing bFGF under doxycycline control , 2013, Experimental Neurology.

[147]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[148]  A. Rawat,et al.  Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting.

[149]  M. Einarson Controlled-release microchip , 1999, Nature Biotechnology.

[150]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[151]  S I Simon,et al.  Neutrophil transendothelial migration is independent of tight junctions and occurs preferentially at tricellular corners. , 1997, Journal of immunology.

[152]  P. Couraud Infiltration of inflammatory cells through brain endothelium. , 1998, Pathologie-biologie.

[153]  W. Pardridge Recent developments in peptide drug delivery to the brain. , 1992, Pharmacology & toxicology.

[154]  Hartwig Wolburg,et al.  Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.

[155]  Kwangmeyung Kim,et al.  Nano-enabled delivery systems across the blood–brain barrier , 2013, Archives of Pharmacal Research.

[156]  E. Neuwelt,et al.  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.

[157]  A. Fadda,et al.  Liposomes for brain delivery , 2013, Expert opinion on drug delivery.

[158]  Qing-hui Zhou,et al.  Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. , 2011, Bioconjugate chemistry.

[159]  N. Shaik,et al.  Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.

[160]  N. Saunders Faculty of 1000 evaluation for Getting into the brain: approaches to enhance brain drug delivery. , 2016 .

[161]  E. Snyder,et al.  Neurotransplantation of stem cells genetically modified to express human dopamine transporter reduces alcohol consumption , 2010, Stem Cell Research & Therapy.

[162]  G. Bonvento,et al.  Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study , 1998, Glia.

[163]  W. Thomas,et al.  Brain macrophages: on the role of pericytes and perivascular cells , 1999, Brain Research Reviews.

[164]  I. Romero,et al.  Transporting therapeutics across the blood-brain barrier. , 1996, Molecular medicine today.

[165]  P. A. Peterson,et al.  The Roles of Claudin Superfamily Proteins in Paracellular Transport , 2001, Traffic.

[166]  G. Vassal,et al.  Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.

[167]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[168]  B. Geiger,et al.  The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha- catenin with vascular endothelial cadherin (VE-cadherin) , 1995, The Journal of cell biology.

[169]  Amit Modgil,et al.  Influence of Short-Chain Cell-Penetrating Peptides on Transport of Doxorubicin Encapsulating Receptor-Targeted Liposomes Across Brain Endothelial Barrier , 2014, Pharmaceutical Research.

[170]  S. Stenglein,et al.  Morphological and functional characterization of an in vitro blood–brain barrier model , 1997, Brain Research.

[171]  R. Bartus,et al.  Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. , 2000, The Journal of pharmacology and experimental therapeutics.

[172]  W. Saltzman,et al.  Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. , 1994, Cancer research.

[173]  M. Mayberg,et al.  Mechanisms of glucose transport at the blood–brain barrier: an in vitro study , 2001, Brain Research.

[174]  H. Brem,et al.  New directions in the delivery of drugs and other substances to the central nervous system. , 1991, Advances in pharmacology.

[175]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[176]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[177]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[178]  J. Lai,et al.  Brain metabolism and specific transport at the blood- brain barrier after portocaval anastomosis in the rat , 1979, Brain Research.

[179]  G. Miller Drug targeting. Breaking down barriers. , 2002, Science.

[180]  Sara Eyal,et al.  Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.

[181]  S. Tsukita,et al.  Manner of Interaction of Heterogeneous Claudin Species within and between Tight Junction Strands , 1999, The Journal of cell biology.

[182]  P. McCrea,et al.  Purification of a 92-kDa cytoplasmic protein tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin). Characterization and extractability of the protein complex from the cell cytostructure. , 1991, The Journal of biological chemistry.

[183]  G. Turner,et al.  Breaking down the blood-brain barrier: signaling a path to cerebral malaria? , 2002, Trends in parasitology.

[184]  H. Hirschberg,et al.  Site‐specific opening of the blood‐brain barrier , 2010, Journal of biophotonics.

[185]  W. Pardridge,et al.  Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  L. Sobrevia,et al.  Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. , 2003, Physiological reviews.

[187]  D. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[188]  W. Pardridge,et al.  Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.

[189]  M. Takeichi,et al.  p120ctn Acts as an Inhibitory Regulator of Cadherin Function in Colon Carcinoma Cells , 1999, The Journal of cell biology.

[190]  P. Gaillard Case study: to-BBB's G-Technology, getting the best from drug-delivery research with industry-academia partnerships. , 2011, Therapeutic delivery.

[191]  Luca Cucullo,et al.  Development of a Humanized In Vitro Blood–Brain Barrier Model to Screen for Brain Penetration of Antiepileptic Drugs , 2007, Epilepsia.